Inovio: $24M for cancer vaccine

Cancer vaccine developer Inovio, of Blue Bell, says it's raised $24.3 million in a share and warrant sale via Roth Capital Partners LLC, to "fully fund our planned Phase II clinical study for our DNA vaccine against cervical dysplasias and cancers, as well as other clinical studies that Inovio intends to directly fund and launch in 2011," said chief executive Dr. J. Joseph Kim in this statement.